BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34994387)

  • 1. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.
    Mortazavi A; Fayed I; Bachani M; Dowdy T; Jahanipour J; Khan A; Owotade J; Walbridge S; Inati SK; Steiner J; Wu J; Gilbert M; Yang CZ; Larion M; Maric D; Ksendzovsky A; Zaghloul KA
    Neuro Oncol; 2022 Sep; 24(9):1423-1435. PubMed ID: 34994387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
    Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
    Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
    Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
    [No Abstract]   [Full Text] [Related]  

  • 4. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
    Wahl DR; Venneti S
    Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
    Pichumani K; Mashimo T; Baek HM; Ratnakar J; Mickey B; DeBerardinis RJ; Maher EA; Bachoo RM; Malloy CR; Kovacs Z
    Anal Biochem; 2015 Jul; 481():4-6. PubMed ID: 25908561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
    Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
    Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of 2-hydroxyglutarate as a controversial oncometabolite in malignant gliomas.
    Bystricky P; Kasubova I; Richterova R; Lasabova Z; Kolarovszki B
    Neoplasma; 2020 Nov; 67(6):1367-1372. PubMed ID: 32853017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
    Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
    Rudà R; Bruno F; Pellerino A
    Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactate dehydrogenase A silencing in IDH mutant gliomas.
    Chesnelong C; Chaumeil MM; Blough MD; Al-Najjar M; Stechishin OD; Chan JA; Pieper RO; Ronen SM; Weiss S; Luchman HA; Cairncross JG
    Neuro Oncol; 2014 May; 16(5):686-95. PubMed ID: 24366912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
    Kim H; Kim S; Lee HH; Heo H
    Korean J Radiol; 2016; 17(5):620-32. PubMed ID: 27587950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
    Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
    Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.